Episurf Medical’s Episealer® procedure and products are approved for payment by the U.K. Spire Hospitals and the Dutch health insurance companies, VGZ and Multiorg.
Further, the Belgium reimbursement authority RIZIV (The National Institute for Health and Disability Insurance) approved the Episealer Femoral Twin implant, thus clearning the entire portfolio (Condyle Solo, Trochlea Solo and Femoral Twin) for payment by the Belgium authority.
This activity supports Episurf’s plan to achieve private health sector reimbursement. Episurf’s patient-specific implants and Epiguide® drill guides are designed to treat localized cartilage injury in joints.
Episurf is prepping for U.S. market entry. Experien Group has recommended a pre-510(k) submission meeting with FDA to discuss their technology, proposed indications for use and proposed performance testing.
Episurf Medical's Episealer® procedure and products are approved for payment by the U.K. Spire Hospitals and the Dutch health insurance companies, VGZ and Multiorg.
Further, the Belgium reimbursement authority RIZIV (The National Institute for Health and Disability Insurance) approved the Episealer Femoral Twin implant, thus clearning the...
Episurf Medical’s Episealer® procedure and products are approved for payment by the U.K. Spire Hospitals and the Dutch health insurance companies, VGZ and Multiorg.
Further, the Belgium reimbursement authority RIZIV (The National Institute for Health and Disability Insurance) approved the Episealer Femoral Twin implant, thus clearning the entire portfolio (Condyle Solo, Trochlea Solo and Femoral Twin) for payment by the Belgium authority.
This activity supports Episurf’s plan to achieve private health sector reimbursement. Episurf’s patient-specific implants and Epiguide® drill guides are designed to treat localized cartilage injury in joints.
Episurf is prepping for U.S. market entry. Experien Group has recommended a pre-510(k) submission meeting with FDA to discuss their technology, proposed indications for use and proposed performance testing.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
